Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)
Analysts fell to the sidelines weighing in on Exelixis (EXEL – Research Report), Hims & Hers Health (HIMS – Research Report) and Regeneron (REGN – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Exelixis (EXEL)
Morgan Stanley analyst Sean Laaman maintained a Hold rating on Exelixis yesterday and set a price target of $49.00. The company’s shares closed last Friday at $41.55.
According to TipRanks.com, Laaman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $46.67 average price target, which is a 15.1% upside from current levels. In a report issued on March 1, RBC Capital also maintained a Hold rating on the stock with a $43.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Hims & Hers Health (HIMS)
Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on Hims & Hers Health today and set a price target of $21.00. The company’s shares closed last Friday at $15.74, close to its 52-week low of $11.20.
Hettenbach has an average return of
According to TipRanks.com, Hettenbach is ranked #2867 out of 12122 analysts.
Hims & Hers Health has an analyst consensus of Hold, with a price target consensus of $23.23, which is a 49.5% upside from current levels. In a report issued on February 23, BTIG also downgraded the stock to Hold with a price target.
Regeneron (REGN)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Regeneron yesterday and set a price target of $769.00. The company’s shares closed last Friday at $759.86.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $875.30, which is a 15.9% upside from current levels. In a report issued on March 2, RBC Capital also maintained a Hold rating on the stock with a $765.00 price target.
